Based on the antibody levels, survival rates, and tissue viral load test, it can be concluded that the APS–Vaccine group effectively increased IgM levels, improved survival rates, alleviated tissue virus load, and prevented viral infection. This evidence concerns the gene CD40LG and viral infectious disease.